Highlights

  • CurveBeam AI received FDA 510(k) clearance for its BoneVue bone mineral density CT module in September 2026, the first step toward adding a recurring SaaS Revenue stream to placed HiRise units.
  • Wego Orthopedics in China received NMPA approval for the HiRise scanner and placed an initial order for 10 units, with the next 40-unit Tranche targeted in the first half of 2027.
  • Validation of HiRise for use with multiple robotic surgical platforms is in progress, targeting the growing CT-dependent pre-operative planning workflow in orthopaedic robotics.
  • CurveBeam AI has 70-plus HiRise units deployed globally across four continents, with a co-marketing agreement with Stryker Foot & Ankle supporting US distribution.

CurveBeam AI Limited (ASX:CVB) addressed the NWR Healthcare Technology Lunch audience in Melbourne in November 2026 with a presentation framed around a central clinical and commercial insight: orthopaedic imaging that captures the musculoskeletal system under natural body weight generates clinically superior information compared with imaging acquired with the patient lying flat. This is not simply a technical preference but a clinically validated difference — the weight-bearing condition changes joint alignment, loading mechanics and bone relationships in ways that are directly relevant to surgical planning and implant selection. The company's HiRise™ scanner is designed to perform both standing weight-bearing CT and conventional supine CT from a compact footprint that fits within a group surgeon practice or ambulatory surgical centre, without the radiation dose, shielding requirements, specialist staffing or large-footprint infrastructure associated with conventional hospital CT systems. This combination of clinical capability and practical deployability in the orthopaedic practice setting is what CurveBeam AI considers its core value proposition.

BoneVue BMD Clearance and the SaaS Revenue Model

The September 2026 FDA 510(k) clearance for CurveBeam AI's BoneVue bone mineral density module for multidetector CT systems represents a significant milestone in the company's strategy to build a recurring, annuity-like revenue layer on top of its hardware business. Bone mineral density testing is currently performed primarily via dedicated DXA imaging in a separate clinical appointment — an inconvenience for patients and an inefficiency in the orthopaedic care workflow, particularly for the elderly patients who most commonly require joint replacement and who also face the highest risk of bone density-related implant complications. The BoneVue clearance for multidetector CT opens the door to a Special 510(k) application to extend the same functionality onto the HiRise platform, which would allow a surgeon group practice to offer BMD assessment within the same clinical encounter as the weight-bearing CT scan. Each HiRise unit that becomes a combined CT-and-BMD imaging platform gains an additional revenue stream from repeat BMD assessments, transforming a one-time Capital equipment sale into a source of ongoing software-based income estimated at an Annuity potential per unit per year.

The China Market Through Wego Orthopedics

CurveBeam AI's most commercially significant recent announcement has been the first tangible output of its Chinese Partnership with Wego Orthopedics — the receipt of China NMPA regulatory approval for the US-manufactured HiRise scanner, followed by an initial purchase order for 10 units. This first tranche of units, valued at approximately AU$4.3 million in sales, was accompanied by an Equity Investment from Wego and represents the opening commercial deployment of HiRise in one of the world's largest and most dynamic healthcare markets. A second milestone targets the Placement of an additional 40 units, representing further sales of approximately AU$17.6 million. Beyond the sales volume, the Chinese market carries strategic significance: Wego is positioning to become a significant participant in the Chinese orthopaedic robotics market, and CurveBeam AI's technology may become an integrated component of robotic surgical workflows deployed through Wego's commercial network, creating a potentially large installed base of HiRise units within a growing robotic surgery ecosystem.

Robotic Surgery: The CT Dependency Opportunity

The accelerating adoption of robotic-assisted orthopaedic surgery systems is creating a structural tailwind for CurveBeam AI that the company is actively working to capitalise on. The key dynamic is that several leading robotic platforms require pre-operative CT imaging to generate the three-dimensional bone models and patient-specific cutting guides that enable precision robotic surgery. At present, this CT requirement is typically fulfilled by referring patients to a radiology facility, introducing a delay between clinical consultation and surgical planning and generating no CT revenue for the surgeon group. If HiRise can be validated for use in robotic surgery pre-planning workflows, surgeon groups can perform the required CT scan at the time of consultation using their own installed HiRise unit — compressing the patient journey, capturing imaging revenue in-house and improving the overall workflow efficiency. CurveBeam AI is pursuing validation across multiple robotic platforms including work associated with the Stryker MAKO system and others, with a range of manufacturers from Globus Medical, Medacta and Newclip as additional targets.

Key Insights

CurveBeam AI's investment thesis rests on three converging opportunities: the ongoing rollout of HiRise into orthopaedic practices as the primary point-of-care CT tool, the addition of BMD-based recurring SaaS revenue to the hardware model, and the structural tailwind from robotic surgery's CT dependency. The China Wego partnership adds a large-volume geographic dimension that could materially expand the global installed base. The near-term milestones most likely to drive investor attention are the Wego 40-unit second tranche order, the HiRise BMD 510(k) submission and the completion of robotic platform validations — each of which would demonstrate advancement along one of the company's three key revenue vectors.